These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 24298897)

  • 1. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
    BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
    Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
    Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
    Fizazi K; Jones R; Oudard S; Efstathiou E; Saad F; de Wit R; De Bono J; Cruz FM; Fountzilas G; Ulys A; Carcano F; Agarwal N; Agus D; Bellmunt J; Petrylak DP; Lee SY; Webb IJ; Tejura B; Borgstein N; Dreicer R
    J Clin Oncol; 2015 Mar; 33(7):723-31. PubMed ID: 25624429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
    Michaelson MD; Oudard S; Ou YC; Sengeløv L; Saad F; Houede N; Ostler P; Stenzl A; Daugaard G; Jones R; Laestadius F; Ullèn A; Bahl A; Castellano D; Gschwend J; Maurina T; Chow Maneval E; Wang SL; Lechuga MJ; Paolini J; Chen I
    J Clin Oncol; 2014 Jan; 32(2):76-82. PubMed ID: 24323035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
    Teply BA; Luber B; Denmeade SR; Antonarakis ES
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
    Pond GR; Berry WR; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Clin Genitourin Cancer; 2012 Dec; 10(4):239-45. PubMed ID: 23000202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
    Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
    Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
    Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
    Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
    Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
    Hussain M; Rathkopf D; Liu G; Armstrong A; Kelly WK; Ferrari A; Hainsworth J; Joshi A; Hozak RR; Yang L; Schwartz JD; Higano CS
    Eur J Cancer; 2015 Sep; 51(13):1714-24. PubMed ID: 26082390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
    Morris MJ; Molina A; Small EJ; de Bono JS; Logothetis CJ; Fizazi K; de Souza P; Kantoff PW; Higano CS; Li J; Kheoh T; Larson SM; Matheny SL; Naini V; Burzykowski T; Griffin TW; Scher HI; Ryan CJ
    J Clin Oncol; 2015 Apr; 33(12):1356-63. PubMed ID: 25624432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
    Parimi S; Eliasziw M; North S; Trudeau M; Winquist E; Chi KN; Ruether D; Cheng T; Eigl BJ
    Invest New Drugs; 2016 Dec; 34(6):771-776. PubMed ID: 27565809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.